Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor SAR442168

STATUS

Recruiting
participants needed

1290
sponsor

Sanofi

Send

Updated on 19 February 2024

See if I qualify

multiple sclerosis

contraceptive use

chronic progressive multiple sclerosis

secondary progressive multiple sclerosis

Summary

Primary Objective:

To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS

Secondary Objective:

To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites in NRSPMS and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168

Description

Study duration will vary per participant in this event driven trial with a treatment duration of approximately 24 to 48 months. Participants completing the treatment period will be proposed to enroll in a separate Long term safety study.

Details

Condition	Multiple Sclerosis, Multiple Sclerosis, Chronic progressive multiple sclerosis, secondary progressive multiple sclerosis
Age	18-60 years
Treatment	SAR442168, Placebo to match SAR442168
Clinical Study Identifier	NCT04411641
Sponsor	Sanofi
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	to 60 years of age inclusive
	Diagnosis of nonrelapsing secondary progressive multiple sclerosis according to the 2017 McDonald criteria
	Expanded disability status scale (EDSS) between 3.0 to 6.5 points inclusive, at screening
	The participant must have documented evidence of disability progression observed during the 12 months before screening
	Absence of clinical relapses for at least 24 months
	The participant must have, at screening, disease duration from the onset of MS symptoms of
	<20 years in participants with EDSS scores at screening >5.0; OR
	<10 years in participants with EDSS scores at screening 5.0
	Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
	A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies
	Is not a WOCBP OR
	Is a WOCBP and agrees to use an acceptable contraceptive method
Exclusion Criteria
	The participant has conditions that would adversely affect study participation such as short life expectancy
	History of organ transplant
	Evidence of infection with human immuodeficiency virus (HIV), progressive multifocal leukoencephalopathy (PML), active hepatitis B or C, active or latent tuberculosis or other active infections that would adversely affect study participation
	History of malignancy within 5 years prior to screening
	History of alcohol or drug abuse within 1 year prior to screening
	Hospitalized for psychiatric disease within 2 years prior to screening
	Clinically significant laboratory abnormalities (including evidence of liver injury) or electrocardiogram abnormalities at screening
	Bleeding disorder, known platelet dysfunction or platelet count <150 000/L at screening
	A history of significant bleeding event within 6 months prior to screening, according to the Investigator's judgment such as, but not limited to cerebral or gastrointestinal bleeding
	Lymphocyte count below the lower limit of normal at screening
	Recent live (attenuated) vaccine within 2 months before the first treatment visit
	Recent major surgery (within 4 weeks of screening) or planned major surgery during the study
	The participant has received medications/treatments for MS within a specified time frame
	Receiving strong inducers or inhibitors of cytochrome P450 3A (CYP3A) or CYP2C8 hepatic enzymes
	Receiving anticoagulant or antiplatelet therapy (such as aspirin, clopidogrel, warfarin)
	Contraindications to magnetic resonance imaging (MRI)
	The above information is not intended to contain all considerations relevant
	to a patient's potential participation in a clinical trial

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

multiple sclerosis

contraceptive use

chronic progressive multiple sclerosis

secondary progressive multiple sclerosis

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor SAR442168